World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
121
Citations
59802
World Ranking
526
National Ranking
311

Medicine

D-Index
122
Citations
61605
World Ranking
3445
National Ranking
1894

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Susan E. Bates is affiliated with Columbia University in the United States and has a research portfolio consisting primarily of work in medicine and biochemistry, genetics, and molecular biology. Their publications span several subfields including oncology, molecular biology, pulmonary and respiratory medicine, cancer research, and surgery. Their research topics cover pancreatic and hepatic oncology research, cancer genomics and diagnostics, histone deacetylase inhibitors research, cutaneous lymphoproliferative disorders research, renal cell carcinoma treatment, cholangiocarcinoma and gallbladder cancer studies, and epigenetics and DNA methylation.

Notable recent papers include:

  • Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial (2023, The Lancet)
  • Epigenetic Therapies for Cancer (2020, New England Journal of Medicine)
  • Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma (2020, Journal of Clinical Oncology)
  • Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance (2021, Nature Communications)
  • HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA) (2020, Journal of Clinical Oncology)

The scientist has collaborated frequently with a group of co-authors including:

  • Tito Fojo
  • Mengxi Zhou
  • Antonio Tito Fojo
  • Gulam A. Manji
  • Lawrence H. Schwartz

Their work is published recurrently in several scientific venues, with the highest number of publications appearing in:

  • The Oncologist
  • Journal of Clinical Oncology
  • Seminars in Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Research

Best Publications

  • Multidrug resistance in cancer: role of ATP–dependent transporters

    Michael M. Gottesman;Tito Fojo;Susan E. Bates

  • Tumour stem cells and drug resistance

    Michael Dean;Tito Fojo;Susan Bates

  • Revisiting the role of ABC transporters in multidrug-resistant cancer

    Robert W. Robey;Kristen M. Pluchino;Matthew D. Hall;Antonio T. Fojo;Antonio T. Fojo

  • An Information-Intensive Approach to the Molecular Pharmacology of Cancer

    John N. Weinstein;Timothy G. Myers;Patrick M. O'Connor;Stephen H. Friend

  • The Role of ABC Transporters in Clinical Practice

    Gregory D. Leonard;Tito Fojo;Susan E. Bates

  • Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.

    Keisuke Miyake;Lyn Mickley;Thomas Litman;Zhirong Zhan

  • From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.

    T. Litman;T. E. Druley;W. D. Stein;S. E. Bates

  • Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

    Richard L. Piekarz;Robin Frye;Maria Turner;John J. Wright

  • Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart.

    Cindy M. Martin;Annette P. Meeson;Scott M. Robertson;Thomas J. Hawke

  • The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)

    Thomas Litman;Mariafiorella Brangi;Eric Hudson;Patricia Fetsch

  • Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

    Richard L. Piekarz;Rob Robey;Victor Sandor;Susan Bakke

  • Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

    Victor Sandor;Susan Bakke;Robert W Robey;Min H Kang

  • Use of the polymerase chain reaction in the quantitation of MDR-1 gene expression

    Lizabeth Deutsch Murphy;Cynthia Elaine Herzog;Joanthan Brett Rudick;Antonio Tito Fojo

  • ABCG2: a perspective.

    Robert W. Robey;Kenneth K.K. To;Orsolya Polgar;Marius Dohse

  • Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

    Richard L. Piekarz;Robin Frye;H. Miles Prince;Mark H. Kirschbaum

  • ABCG2: determining its relevance in clinical drug resistance.

    Robert W. Robey;Orsolya Polgar;John Deeken;Kin Wah To

  • Methods to Detect P-Glycoprotein-associated Multidrug Resistance in Patients' Tumors: Consensus Recommendations

    William T. Beck;Thomas M. Grogan;Cheryl L. Willman;Carlos Cordon-Cardo

  • Strategies for reversing drug resistance.

    Tito Fojo;Susan Bates

  • Autocrine and paracrine growth regulation of human breast cancer

    Marc E. Lippman;Robert B. Dickson;Susan Bates;Cornelius Knabbe

  • Characterization of estrogen responsive transforming activity in human breast cancer cell lines

    Robert B. Dickson;Susan E. Bates;Mary E. McManaway;Marc E. Lippman

Frequent Co-Authors

Tito Fojo
Tito Fojo Columbia University
William D. Figg
William D. Figg National Institutes of Health
Suresh V. Ambudkar
Suresh V. Ambudkar National Institutes of Health
Thomas Litman
Thomas Litman University of Copenhagen
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
Wilfred D. Stein
Wilfred D. Stein Hebrew University of Jerusalem
Marc E. Lippman
Marc E. Lippman National Institutes of Health
Michael Dean
Michael Dean National Institutes of Health
Michael M. Gottesman
Michael M. Gottesman National Institutes of Health
Wyndham H. Wilson
Wyndham H. Wilson National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re planning to study Medicine in the USA, there are a number of related online degrees and career pathways to consider. Many students begin their journey in healthcare with flexible and accessible online nursing programs, which can offer a more affordable or convenient route into the medical field. For example, those looking for cost-effective options may want to explore the cheapest accredited online rn to bsn programs available today.

If you're seeking a faster entry into advanced nursing roles, look into online direct entry msn programs, which allow non-nurses with a bachelor’s degree in another field to earn a Master of Science in Nursing. Some may begin their pathway with online adn programs for non nurses, providing a quick, accessible route into the nursing profession from scratch.

For those interested in healthcare but not direct patient care, medical billing and coding schools that accept financial aid can be a great option. These programs teach vital skills for supporting hospitals and clinics, often with flexible schedules and financial assistance available.

Best Scientists Citing Susan E. Bates

Trending Scientists

Recently Published Articles